1.
|
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: COLOGEN, NCT00138060
|
|
2.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
3.
|
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: KA05030-MA, KA05030, NCT00300547
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML20592, NCT00502671
|
|
5.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 01-07, NCT00535652
|
|
6.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CHUL-BIO-COLON, RECF0356, INCA-RECF0356, NCT00559676
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21380, NCT00577031
|
|
8.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 75 and over
Sponsor: Other
Protocol IDs: I07028, N° EudraCT : 2008-001195-7, NCT00812864
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2009-03, NCT00868569
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2009-04, NCT00874406
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2GI/001 Part III, LC001Auron2005, NCT00405561
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2241, NCT00419159
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: Flav-Hoe-CCC, NCT00609310
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2007_529, MK0646-004, NCT00614393
|
|
16.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STX0206, NCT00724503
|
|
17.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 08-PIR-03, NCT00856375
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GRECCR-03, EU-20201, NCT00046995
|
|
19.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCCTG-N0147, ECOG-N0147, N0147, NCT00079274
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: JCOG0404, C000000105, NCT00147134
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRE-2002.445-T, NCT00164879
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: HGCSG-CAD, NCT00209742
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AERO-MC04, NCT00189683
|
